E. Berrak

发表

Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancer

J. O’Shaughnessy, S. Puhalla, L. Schwartzberg, 2019, BMC Cancer.

Multivariate and subgroup analyses of a randomized, multinational, phase 3 trial of decitabine vs treatment choice of supportive care or cytarabine in older patients with newly diagnosed acute myeloid leukemia and poor- or intermediate-risk cytogenetics

H. Kantarjian, F. Ravandi, X. Thomas, 2014, BMC Cancer.

Impact of prior anthracycline or taxane use on eribulin effectiveness as first-line treatment for metastatic breast cancer: results from two phase 2, multicenter, single-arm studies

J. O’Shaughnessy, S. Puhalla, L. Schwartzberg, 2015, SpringerPlus.

Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for human epidermal growth factor receptor 2 positive locally recurrent or metastatic breast cancer: results from a Phase II, single-arm, multicenter study

J. O’Shaughnessy, A. Brufsky, S. Puhalla, 2016, Breast cancer.

A post hoc sensitivity analysis of survival probabilities in a multinational phase III trial of decitabine in older patients with newly diagnosed acute myeloid leukemia.

H. Kantarjian, X. Thomas, J. Delaunay, 2014, Clinical lymphoma, myeloma & leukemia.

Association between Treatment Response and Potential Indicators of Efficacy and Safety in a Phase III Trial of Decitabine in Older Patients with Acute Myeloid Leukemia

M. Minden, H. Kantarjian, Mark M. Jones, 2015 .

Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy

F. Marmé, X. Pivot, A. Wolfer, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancer

J. O’Shaughnessy, S. Puhalla, L. Schwartzberg, 2019, BMC Cancer.

Phase 2, multicenter, single-arm study of eribulin mesylate with trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer.

J. O’Shaughnessy, S. Puhalla, L. Schwartzberg, 2014, Clinical breast cancer.

Post hoc analysis of the relationship between baseline white blood cell count and survival outcome in a randomized Phase III trial of decitabine in older patients with newly diagnosed acute myeloid leukemia

H. Kantarjian, X. Thomas, J. Delaunay, 2015, Journal of blood medicine.

Multivariate and Subgroup Analyses of a Multinational Phase III Trial of Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia

H. Kantarjian, X. Thomas, J. Delaunay, 2012 .

Multivariate and subgroup analyses of a randomized, multinational, phase 3 trial of decitabine vs treatment choice of supportive care or cytarabine in older patients with newly diagnosed acute myeloid leukemia and poor- or intermediate-risk cytogenetics

H. Kantarjian, F. Ravandi, X. Thomas, 2014, BMC Cancer.

Safety and tolerability of eribulin mesylate in patients with pretreated metastatic breast cancer.

S. Goodin, James X. Song, S. Barbour, 2015, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Relationship between baseline white blood cell count and renal and hepatic function in older patients with acute myeloid leukemia☆☆☆

M. Minden, H. Kantarjian, J. Delaunay, 2013, Leukemia research reports.

Gilteritinib versus chemotherapy in Japanese patients with FLT3-mutated relapsed/refractory acute myeloid leukemia

T. Naoe, S. Fujiwara, M. Kizaki, 2021, International Journal of Clinical Oncology.

Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer

J. O’Shaughnessy, S. Glück, L. Schwartzberg, 2014, Breast Cancer Research and Treatment.

Erratum to: Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer

J. O’Shaughnessy, S. Glück, L. Schwartzberg, 2014, Breast Cancer Research and Treatment.

Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin Combined With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive, Early-Stage Breast Cancer.

J. O’Shaughnessy, S. Vukelja, James X. Song, 2016, Clinical breast cancer.